Japanese cedar pollinosis
Conditions
Interventions
Intake of 5g 1-kestose for 56 days in the morning every day
As placebo, intale of maltose for 56 days in the morning every day
Sponsors
Department of Clinical Application of Biologics, Osaka University Graduate School of Medicie
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Assertion of document informed consent 2. Persons who had previously presented with allergic symptoms such as sneezing, rhinorrhea or nasl obstruction in association with exposure of Japanese cedar pollen 3. Persons who live in or within 50 Km apart from Chita City.
Exclusion criteria
Exclusion criteria: 1. Due to chronic diseases or difficulty in describing their symptom scores in the symptom dairy or qestionnaire, persons are not appropriate for the entry by doctors' evaluation. 2. Persons who take functional foods including probiotics or prebiotics in order to suppress allerguc symotoms 3. Persons who receive or will receive immunotherapy against Japanese cedar pollinosis 4. Persons who continuously take anti bacterial drug 5. Pregnant, lactating women or women who are planning a pregnancy 6. Persons who are enrolled into other clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of symptom score (rhinorrhea, sneezing, nasal obstruction, nose itching, eye itching, lacrimation; severity 0~4) | — |
Secondary
| Measure | Time frame |
|---|---|
| QOL score, Drug usage score, Symptom+drug usage score, Intestinal flora, Adverse events | — |
Countries
Japan
Contacts
Public ContactToshio Tanaka
Department of Clinical Application of Biologics Osaka University Graduate School of Medicine
Outcome results
None listed